Mifamurtide

"目录号: HY-13682

Membrane Transporter/Ion Channel-

Mifamurtide(CGP19835; MTP-PE)可作用于骨肉瘤。

TRP Channel

相关产品

Rosiglitazone-Capsazepine-Capsaicin-SKF-96365 hydrochloride-Probenecid-HC-030031-PF-4840154-SAR7334-AMG 517-SB-705498-Icilin-GSK1016790A-RN-1734-ML204-HC-067047-

生物活性

Description

Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].

Clinical Trial

NCT00631631

Millennium Pharmaceuticals, Inc.

Osteosarcoma

January 2008

NCT02441309

University of Oxford-Millennium: The Takeda Oncology Company-National Institute for Health Research, United Kingdom-Oxford University Hospitals NHS Trust-European Commission

Osteosarcoma

October 2014

Phase 2

NCT01194284

Millennium Pharmaceuticals, Inc.-Takeda

Osteosarcoma

December 2011

NCT01459484

Italian Sarcoma Group

Osteosarcoma

July 2011

Phase 2-Phase 3

NCT00000972

National Institute of Allergy and Infectious Diseases (NIAID)-Biocine

HIV Infections-HIV Seronegativity

Phase 1

NCT00001019

National Institute of Allergy and Infectious Diseases (NIAID)-Biocine

HIV Infections

Phase 1

NCT00000958

National Institute of Allergy and Infectious Diseases (NIAID)-Biocine

HIV Infections

Phase 1

NCT00001042

National Institute of Allergy and Infectious Diseases (NIAID)

HIV Infections

Phase 1

View MoreCollapse

References

[1].Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs, 2010. 12(3): p. 141-53.

[2].Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.